We have expertise in performing ELISA assays. For instance, we use the ELISA kit for IL-12 and IL-10 from Biosource to evaluate cytokine accumulation in supernatants at 24h, according to a standard protocol and it was measured at 450n

We have know-how on TaqMan gene expression assays by Perkin-Elmer Applied Biosystems. They are used, for instance, for PCR analysis.

In our labs we have experience in performing immunohistochemistry, e.g., for studying the cellular organization of the marrow of long bones.

We have experience with the exponentially modified Protein Abundance Index (emPAI) method, a label free spectral counting procedure for determining relative protein amounts of LC-MS/MS data. A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. The criteria applied resulted in a list of 2794 unique proteins that were identifie...

In our work, we have experience in applying peptide-tetramer assays. Primary and secondary CTL response against the C8 T cell epitope SIINFEKL was monitored in a study for maturing myeloid DCs and plasmacytoid DCs.

An assay for measuring cytotoxic T lymphocytes was used for the monitoring of T cell activation in the evaluation of the immunotherapy potential of DC pulsed with tumor antigens.

Our laboratory has expertise in applying a fluorescence microscopy method to analyse proximal signalling events induced by cross-linking C-type lectins.

These bioassays were designed taking advantage of some results obtained by performing global gene expression analyses. We have optimised a DC-based assay aimed at identifying new adjuvant molecules potentially capable to induce Th1 responses. This bioassay is a list of standardized procedures, which enables to use the dendritic cells as tools for the determination of the effects of new chemical compounds on dendritic cell capacity to produce type I IFNs.

This bioassay is a list of standardized procedures, which enables to use the dendritic cells as tools for the determination of the effects of new chemical compounds on dendritic cell capacity to produce type I IFNs. The selected molecules could be potential new vaccine adjuvants.

There is know-how on classical MLR assays in our lab. They are used, for instance, for characterization of silenced cells.

We have experience on performing immunofluorescence assays. As an example, an assay on ordered sequential sections was used to analyze the infiltration and destruction of solid tumors by CTLs.

Experience has been gained in identifying DC presenting a specific peptide via a sensitive immunofluorescent staining technique.

The laboratory has expertise in the use of MACS anti-CD14 microbeads by Miltenyi Biotec, Bergisch-Gladbach, Germany. They were used for isolation of monocytes from PBMCs.

In our laboratory we perform 51Cr-release assays, for instance in the monitoring of vaccine induced T cell responses.

Our lab has know-how in performing 3H-thymidine-incorporation assays. This assay was used in the monitoring of vaccine induced T cell responses.

In our laboratory, we have experience in performing CBA assays. We use them, e.g., in the monitoring of vaccine induced T cell responses.

Our lab has expertise in performing thymidine-incorporation assays. The assay is used, for instance, for the monitoring of the vaccine induced specific anti-tumor T cell responses.

We have know-how about LDA assays; for instance, we use LDA assays to monitor vaccine induced T cell responses.

We have expertise on an HSV-based technology for the delivery of antigens to dendritic cells.

We have experience in western blotting, which we use for example for the assessment of the efficiency of gene silencing.